Pancreatic Cancer Trials Don’t Adhere to Eligibility Criteria Guidelines
Overall compliance with eligibility criteria guidelines is low for pancreatic cancer trials, a recent study suggests.
Overall compliance with eligibility criteria guidelines is low for pancreatic cancer trials, a recent study suggests.
Cancer patients living in nursing homes are more likely to receive aggressive end-of-life care and die in the hospital, a study suggests.
Difference in average annual percentage change due to increasing incidence in Blacks, adenocarcinoma histopathological subtype, tumor location.
Implementation of precision oncology recommendations has clinical utility for patients with gastrointestinal cancers.
A retrospective review of records revealed a possible survival benefit for patients with PDAC treated with adjuvant therapy and surgery.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
The gene sequencing panel PancreaSeq can accurately classify pancreatic cysts as benign or potentially cancerous, according to researchers.
Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.
SY-5609 is a highly selective and potent oral inhibitor of the cyclin-dependent kinase 7.
Preoperative FDG-PET may predict pathologic response to neoadjuvant therapy for borderline resectable/locally advanced PDAC.